Related Experiment Video
Updated: Jun 17, 2025

Visualizing Diffusional Dynamics of Gold Nanorods on Cell Membrane using Single Nanoparticle Darkfield Microscopy
Published on: March 5, 2021
CRISPR/Cas13a-assisted amplification-free miRNA biosensor via dark-field imaging and magnetic gold nanoparticles
Jae-Jun Kim1, Jae-Sang Hong1, Hyunho Kim1
1Center for Systems Biology, Massachusetts General Hospital Boston MA 02114 USA im.hyungsoon@mgh.harvard.edu +1 617 643 5679.
Abstract:
MicroRNAs (miRNAs) are short (about 18-24 nucleotides) non-coding RNAs and have emerged as potential biomarkers for various diseases, including cancers. Due to their short lengths, the specificity often becomes an issue in conventional amplification-based methods. Next-generation sequencing techniques could be an alternative, but the long analysis time and expensive costs make them less suitable for routine clinical diagnosis. Therefore, it is essential to develop a rapid, selective, and accurate miRNA detection assay using a simple, affordable system. In this work, we report a CRISPR/Cas13a-based miRNA biosensing using point-of-care dark-field (DF) imaging. We utilized magnetic-gold nanoparticle (MGNPs) complexes as signal probes, which consist of 200 nm-sized magnetic beads and 60 nm-sized gold nanoparticles (AuNPs) linked by DNA hybridization. Once the CRISPR/Cas13a system recognized the target miRNAs (miR-21-5p), the activated Cas13a cleaved the bridge linker containing RNA sequences, releasing 60 nm-AuNPs detected and quantified by a portable DF imaging system. The combination of CRISPR/Cas13a, MGNPs, and DF imaging demonstrated amplification-free detection of miR-21-5p within 30 min at a detection limit of 500 attomoles (25 pM) and with single-base specificity. The CRISPR/Cas13a-assisted MGNP-DF assay achieved rapid, selective, and accurate detection of miRNAs with simple equipment, thus providing a potential application for cancer diagnosis.
Insights
A new CRISPR/Cas13a biosensor combined with magnetic-gold nanoparticles and dark-field imaging offers rapid, specific detection of microRNAs (miRNAs). This simple, point-of-care system shows promise for early cancer diagnosis.
Area of Science:
- Biotechnology
- Molecular Biology
- Nanotechnology
Background:
- MicroRNAs (miRNAs) are crucial biomarkers for diseases like cancer.
- Conventional miRNA detection methods face challenges in specificity, speed, and cost.
- There is a need for rapid, selective, and affordable miRNA detection assays for clinical use.
Purpose of the Study:
- To develop a novel CRISPR/Cas13a-based biosensing platform for microRNA detection.
- To utilize magnetic-gold nanoparticle (MGNP) complexes and dark-field (DF) imaging for signal amplification and detection.
- To establish a rapid, selective, and accurate point-of-care assay for miRNA quantification.
Main Methods:
- A CRISPR/Cas13a system was employed to recognize specific target miRNAs (miR-21-5p).
- Magnetic-gold nanoparticle (MGNP) complexes, linked by DNA, served as signal probes.
- Activated Cas13a cleaved the RNA linker, releasing gold nanoparticles (AuNPs) for detection via portable dark-field imaging.
Main Results:
- The assay achieved amplification-free detection of miR-21-5p within 30 minutes.
- A low detection limit of 500 attomoles (25 pM) was demonstrated.
- Single-base specificity was achieved, highlighting the assay's precision.
Conclusions:
- The developed CRISPR/Cas13a-assisted MGNP-DF assay provides rapid, selective, and accurate miRNA detection.
- The system utilizes simple equipment, making it suitable for point-of-care applications.
- This biosensing approach holds significant potential for early cancer diagnosis.
More Related Videos
09:58Computer Numerical Control Micromilling of a Microfluidic Acrylic Device with a Staggered Restriction for Magnetic Nanoparticle-Based Immunoassays
Published on: June 23, 2022
10:16Author Spotlight: Development of Simplified CRISPR-Based Tests for Rapid Detection of Infectious Diseases
Published on: August 16, 2024